In this paper, we examine three issues associated with normalizing lab data based on reference ranges: normalized values being negative, lab values being excluded because of missing information on reference ranges, and normalized leukocyte differentials not adding up to 100%. We propose solutions to tackle these issues. Even though we propose solutions, we continue to emphasize the importance of using central laboratories as much as possible and regard normalization only as the last resort.
KirbyDSLaboratory testing in clinical trials. In Drug Safety Assessment in Clinical Trials. GilbertGene, ed. New York, NY: Marcel Dekker, Inc; 1993.
2.
PittsNELaboratory parameters and drug safety. Chapter 8 in Drug Safety Assessment in Clinical Trials. GilbertGene, ed. New York, NY: Marcel Dekker, Inc.; 1993.
3.
Chuang-SteinC.Summarizing laboratory data with different reference ranges in multicenter clinical trials. Drug Inf J.1992;26:77–84.
4.
OliverLKChuang-SteinC.Laboratory data in multicenter trials: monitoring, adjustment and summarization. In Drug Safety Assessment in Clinical Trials. GilbertGene, ed. New York, NY: Marcel Dekker, Inc.; 1993.
